Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial ...

Potential high value and de-risked development pathway: Existing human safety and tolerability data from over 470 subjects, from several clinical programs, may help expedite the FDA pathway to ...

When luxury condos and artisanal bakeries move into New York City neighborhoods, Bond No. 9 sometimes follows.

The sector saw an upturn in 2024, with 50 completed IPOs raising $8.52 billion, from $5.06 billion raised in 2023 and marking the highest total IPO value raised since 2021. This rebound, driven by US ...

(RTTNews) - Boehringer Ingelheim and Cue Biopharma, Inc. (CUE), Tuesday, announced a strategic research collaboration and license agreement to develop and commercialize CUE-501. Cue Biopharma's ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, and Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, announced a strategic research ...

Celebrated designer Shaldon Kopman is set to captivate the fashion world once again with his latest collection, Urban Camo, at South African Fashion Week (SAFW). SAFW is scheduled for April 24 to ...

Biophilic environments are becoming essential. As more people experience overstimulation, this return to nature represents a ...

New Delhi: The initial public offerings (IPOs) in the biopharmaceutical sector surged 68.4 per cent to reach $8.52 billion globally in 2024, according to a new report. The sector saw an upturn in ...

We came across a bullish thesis on Mereo BioPharma Group plc (MREO) on Substack by Jake LaMotta. In this article, we will summarize the bulls’ thesis on MREO. Mereo BioPharma Group plc (MREO ...

Can-Fite BioPharma's Namodenoson gains FDA approval for compassionate use in pancreatic cancer; Phase IIa trial underway in Israel. Can-Fite BioPharma Ltd. announced that major U.S. medical ...

We initiate a Buy rating for Benitec Biopharma due to promising early data from BB 301 for OPMD and a cash runway into mid-2027. BB 301 shows potential for meaningful improvements in swallowing ...